IL34 and neoplasm: The latter finding seems to rely on the suppression of angiogenesis as a blockade of IL-34 in mice with established tumor induced by the TNBC cell line 4T1, leading to a dramatic increase in vasculature, thereby restoring the penetration of chemotherapeutic agents and tumor sensitivity to paclitaxel (PTX), one of the standard treatments of TNBC.